Senseonics (SENS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote on key proposals before the meeting date.
Voting matters and shareholder proposals
Election of three directors to serve until the 2029 annual meeting: Timothy T. Goodnow, Francine R. Kaufman, and Sharon Larkin.
Advisory vote on executive compensation (say-on-pay) and on the preferred frequency of future say-on-pay votes, with the board recommending annual votes.
Ratification of KPMG LLP as independent auditors for the fiscal year ending December 31, 2026.
Proposal to amend the certificate of incorporation to double authorized common stock from 70 million to 140 million shares.
Approval of the 2026 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends all director nominees and all proposals for shareholder approval.
Latest events from Senseonics
- 2025 revenue up 60% to $35.3M, with 65–76% growth expected in 2026.SENS
Q4 202529 Apr 2026 - Shareholders will vote on director elections, compensation, share increase, and a new equity plan.SENS
Proxy filing9 Apr 2026 - Six key proposals, including share increase and new equity plan, recommended for approval.SENS
Proxy filing6 Apr 2026 - Virtual meeting to vote on directors, compensation, share increase, and new equity plan.SENS
Proxy filing27 Mar 2026 - 2025 guidance projects $34–38M revenue and a doubling of the global patient base.SENS
Q4 202413 Feb 2026 - Q2 2025 revenue up 37% YoY to $6.6M, gross margin at 46.9%, net loss narrowed to $14.5M.SENS
Q2 20253 Feb 2026 - Launching a one-year CGM sensor and expanding partnerships to capture rapid diabetes market growth.SENS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 18% year-over-year, but losses and funding risks remain as Q4 launch nears.SENS
Q2 20242 Feb 2026 - FDA launch of 365-day CGM spurs demand, but Q3 revenue drops and liquidity risks persist.SENS
Q3 202415 Jan 2026